Neurological manifestations of ATTR amyloidosis

被引:0
|
作者
Pernice, Helena F. F. [1 ,2 ]
Hahn, Katrin [1 ,2 ,3 ]
机构
[1] Charite Univ Med Berlin, Amyloidosis Ctr Charite Berlin ACCB, Charitepl 1, D-10117 Berlin, Germany
[2] Charite Univ Med Berlin, Klin Neurol Expt Neurol, Berlin, Germany
[3] Univ Med Berlin, Berlin Inst Hlth Charite BIH, Berlin, Germany
来源
INNERE MEDIZIN | 2023年 / 64卷 / 09期
关键词
Amyloidosis; hereditary; transthyretin-related; Wild-type amyloidosis; Amyloid neuropathies; Tafamidis; RNA interference; HEREDITARY TRANSTHYRETIN AMYLOIDOSIS; LIVER-TRANSPLANTATION; PROGRESSION; TAFAMIDIS; POLYNEUROPATHY; NEUROPATHY; IMPACT;
D O I
10.1007/s00108-023-01570-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Transthyretin amyloidosis (ATTR) is a rare disease in which the protein transthyretin (TTR) is deposited in the form of amyloid fibrils in various tissues and organs and secondarily leads to functional impairment, especially in peripheral nerves and the heart. A differentiation is made between hereditary and sporadic forms. The hereditary variant is inherited in an autosomal dominant manner and usually occurs in the younger to middle-aged, while the sporadic form occurs in older age and has no known genetic cause. Typical signs of hereditary ATTR amyloidosis (ATTRv, v for variant) include a rapidly progressing sensorimotor and autonomic polyneuropathy (PNP), cardiac dysfunction as well as ocular and gastrointestinal symptoms. A carpal tunnel syndrome often precedes the manifestation. Various options (tafamidis, patisiran, inotersen or vutrisiran) are available for the treatment of patients with ATTRv with PNP in Germany, depending on the severity. In the sporadic variant of wild-type ATTR amyloidosis (ATTRwt), symptoms of progressive cardiomyopathy are usually prominent; however, neurological assessment of these patients often also reveals a concomitant sensory ataxic PNP. The tetramer stabilizer tafamidis can be used for treatment. Because of this complex presentation, the management of patients with ATTR amyloidosis should be performed in interdisciplinary centers specialized in amyloidosis.
引用
收藏
页码:848 / 854
页数:7
相关论文
共 50 条
  • [1] Neurologische Manifestationen der ATTR-AmyloidoseNeurological manifestations of ATTR amyloidosis
    Helena F. Pernice
    Katrin Hahn
    Die Innere Medizin, 2023, 64 (9) : 848 - 854
  • [2] Prevalence and predictors of neurological manifestations in systemic AL amyloidosis
    Thimm, Andreas
    Carpinteiro, Alexander
    Oubari, Sara
    Papathanasiou, Maria
    Luedike, Peter
    Kessler, Lukas
    Rischpler, Christoph
    Blau, Tobias
    Reinhardt, Hans Christian
    Rassaf, Tienush
    Schmidt, Hartmut
    Kleinschnitz, Christoph
    Hagenacker, Tim
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2022, 440
  • [3] Practice of Hereditary ATTR Amyloidosis in Non-endemic Areas of Japan
    Matsushima, Masaaki
    Tarisawa, Monami
    Nomura, Taichi
    Oshima, Yuki
    Yoshino, Masanao
    Shibata, Yuka
    Wakita, Masahiro
    Shirai, Shinichi
    Iwata, Ikuko
    Yaguchi, Hiroaki
    Yabe, Ichiro
    INTERNAL MEDICINE, 2023, 62 (11) : 1599 - 1602
  • [4] Tafamidis in hereditary ATTR amyloidosis - our experience on monitoring the ocular manifestations
    Casal, Ines
    Monteiro, Silvia
    Beirao, Joao Melo
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2016, 23 (04): : 262 - 263
  • [5] Pathogenesis, manifestations, diagnosis, and management of CNS complications in hereditary ATTR amyloidosis
    Sekijima, Yoshiki
    Sousa, Luisa
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2024,
  • [6] Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays
    Kaku, Michelle C.
    Bhadola, Shivkumar
    Berk, John L.
    Sanchorawala, Vaishali
    Connors, Lawreen H.
    Lau, K. H. Vincent
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2022, 29 (03): : 184 - 189
  • [7] Hereditary ATTR Amyloidosis: Burden of Illness and Diagnostic Challenges
    Gertz, Morie A.
    AMERICAN JOURNAL OF MANAGED CARE, 2017, 23 (07) : A107 - A112
  • [8] Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy
    Adams, David
    Suhr, Ole B.
    Dyck, Peter J.
    Litchy, William J.
    Leahy, Raina G.
    Chen, Jihong
    Gollob, Jared
    Coelho, Teresa
    BMC NEUROLOGY, 2017, 17
  • [9] Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review
    Cruz, Marcia Waddington
    CLINICAL AUTONOMIC RESEARCH, 2019, 29 (Suppl 1) : 19 - 24
  • [10] Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review
    Márcia Waddington Cruz
    Clinical Autonomic Research, 2019, 29 : 19 - 24